China (Mainland)
IGD4033 Ligandrol CAS:1165910-22-4 CAS NO.1165910-22-4
- Min.Order: 10 Gram
- Payment Terms: T/T,MoneyGram,Other
- Product Details
Keywords
- IGD4033
- Ligandrol
- SARMS
Quick Details
- ProName: IGD4033 Ligandrol CAS:1165910-22-4
- CasNo: 1165910-22-4
- Molecular Formula: C14H12F6N2O
- Appearance: white powder
- DeliveryTime: 5-8 days
- PackAge: exquisite or according to your require...
- Port: hongkong
- ProductionCapacity: 1000 Kilogram/Month
- Purity: 99%
- Storage: Sealed, dry, microtherm
- LimitNum: 10 Gram
Superiority
Sarm Ligandrol 4033,Buy Cheap Sarms LGD-4033/LGD 4033
Product name: Ligandrol
Brand:HHD
Purity: 98% min
Powder: White or Off White Powder
Other Names:LGD 4033
CAS NO.: 1165910-22-4
M.W.: 441.36
M.F.: C14H12F6N2O
Density: 1.472
Melting Point: 105-107℃
Solubility: DMSO
Details
Ligandrol LGD 4033 powder is a selective androgen receptor modulator a novel non-steroidal, oral SARM that binds to AR with high affinity and selectivity, class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testo sterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.
Function
LGD-4033 works by tying androgen receptors selectively. It shows anabolic activity in the bones and muscles instead of harmfully affecting the prostate and sebaceous glands which usually happens when using steroids. LGD-4033 just concluded a study called Phase I Multiple Ascending Dose which included fit volunteers. This was an unplanned, double bind analysis stage that included a placebo.
Ligandrol LGD 4033 powder is a selective androgen receptor modulator a novel non-steroidal, oral SARM that binds to AR with high affinity and selectivity, class of androgen receptor (AR) ligands that is tissue selective, developed to treat muscle wasting associated with cancer, acute and chronic illness and age-related muscle loss. LGD-4033 is expected to produce the therapeutic benefits of testo sterone with improved safety, tolerability and patient acceptance due to tissue-selective mechanism of action and an oral route of administration.
Function
LGD-4033 works by tying androgen receptors selectively. It shows anabolic activity in the bones and muscles instead of harmfully affecting the prostate and sebaceous glands which usually happens when using steroids. LGD-4033 just concluded a study called Phase I Multiple Ascending Dose which included fit volunteers. This was an unplanned, double bind analysis stage that included a placebo.